Extended Data Fig. 4: Association of baseline tumor characteristics with patient outcomes.
From: Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial
a and b, Association of BM1/BM2 signatures with PFS (a) and best overall response (BOR) (b) in MSS patients (BM1, n = 9; BM2, n = 8; two-tailed Wilcoxon rank sum test). c and d, Association of tumor mutational burden (TMB) at baseline with response (R, n = 7; NR, n = 20; two-tailed Wilcoxon rank sum test) (c) and PFS (PFS > 6M, n = 9; PFS < 6M, n = 19) (d) in MSS patients. e and f, Association of CMS at baseline with PFS (e) and (f) in MSS patients (CMS1, n = 7; CMS4, n = 7; two-tailed Wilcoxon rank sum test).
